| Jul 25 |
Sage Therapeutics cut to Neutral at J.P. Morgan on pipeline concerns
|
| Jul 25 |
Ardelyx (ARDX) Expected to Beat Earnings Estimates: Should You Buy?
|
| Jul 25 |
Sage and Biogen’s SAGE-324 shows no benefit in essential tremor trial
|
| Jul 24 |
Sage, Biogen Shelve Development Of Nervous System Disorder Drug After Data Disappoints
|
| Jul 24 |
Sage Therapeutics Stock Slides as Pipeline Thins
|
| Jul 24 |
Sage Therapeutics Collapses 21% After Biogen-Tied Essential Tremor Drug Fails
|
| Jul 24 |
Biogen, Sage tremor drug fails key trial
|
| Jul 24 |
Biogen, Sage discontinue neuro candidate after mid-stage setback
|
| Jul 24 |
Sage Therapeutics and Biogen Announce Topline Results from Phase 2 KINETIC 2 Study of SAGE-324 (BIIB124) for the Treatment of Essential Tremor
|
| Jul 22 |
Sage Therapeutics/Biogen’s episodic therapy zuranolone could change MDD treatment
|
